Veradermics Prices $384M Stock Offering at $100 After Hair Loss Drug Hits Phase 2/3 Goals
NEW YORK, May 1 —
Veradermics, Incorporated (MANE) priced an upsized 3.84 million-share offering at $100 a share. The deal landed hours after its oral hair loss drug VDPHL01 cleared a Phase 2/3 readout.
- 3.84M shares priced at $100, gross proceeds of roughly $384M before fees
- Stock trades at $99 with a -31.1x forward P/E. The negative multiple says analysts still model cash burn through commercial launch
- A concurrent private placement adds a $300k warrant PIPE on top of the public deal
What Actually Happened
Veradermics ran the textbook biotech double-tap: drop a positive trial result, then sell stock into the rally. VDPHL01 hit its hair growth endpoints in a Phase 2/3 study for male pattern hair loss. Management used the window to upsize the raise and lock in $384M plus the warrant PIPE. Pricing right at $100 against a $99 last print means the book cleared at spot, with no fire-sale discount. For a pre-revenue dermatology company, that is the cleanest possible execution.
The Catch
The clinical de-risking is real. The dilution is also real. A 3.84M-share issuance at $100 resets the float and the per-share math overnight. The -31.1x forward P/E is a reminder that earnings are a long way off. Hair loss is also a category where Propecia (finasteride) has been generic and cheap for two decades. VDPHL01's commercial case rests on a real efficacy or safety edge, not just FDA approval. The next 10-Q will give the first clean look at the post-offering share count and runway.
Bottom Line
This story is more interesting after the news, not less. Veradermics now has data, cash, and a clear path to an NDA filing. That trifecta is rare for a small-cap dermatology name. Growth investors with stomach for binary outcomes get the cleaner setup. Value investors should keep walking. Watch the post-deal share count in the next 10-Q. That number is what turns $384M of headline cash into a real per-share runway figure.
Basis Report has not yet published a full report on MANE. Generate one at /stock/mane to see the full financial breakdown and runway model.
Basis Report does not hold positions in securities discussed. This is not investment advice.